Literature DB >> 10516448

Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group.

T Liukkonen1, P Rajala, M Raitanen, E Rintala, E Kaasinen, P Lipponen.   

Abstract

OBJECTIVE: A prospective randomized study was undertaken to determine whether cell proliferation indices (M/V index, MIB1), papillary status, the expression of p53 and epidermal growth factor receptor (EGFr) have prognostic value in superficial (pTa-pT1) bladder cancer (SBC).
METHODS: 207 patients with primary SBC were followed up over a period of 4.9 (range 3.7-6.0) years. M/V index and papillary status were assessed by light microscopy, and expression of MIB1, p53 and EGFr was assessed by immunohistochemistry. The results of histopathological analyses were related to the survival data of the patients.
RESULTS: Using univariate analysis, stage (p < 0.001), grade (p < 0.001), papillary status (p < 0.001), MIB1 (p < 0.001), M/V index (p < 0.001), EGFr (p < 0.001) and p53 (p = 0.002) were significant predictors of progression. Using multivariate analysis, MIB-1 score and papillary status were independent predictors of progressive disease and cancer-specific survival. Tumor grade was the only independent predictor of recurrence.
CONCLUSION: Evaluation of tumor cell proliferation rate by M/V index or by MIB1 immunohistochemistry and assessment of papillary status by light microscopy are useful prognostic tools in tailoring treatment and follow-up schedule of patients with SBC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516448     DOI: 10.1159/000020039

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

1.  Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.

Authors:  A Quintero; J Alvarez-Kindelan; R J Luque; R Gonzalez-Campora; M J Requena; R Montironi; A Lopez-Beltran
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

Review 2.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer.

Authors:  Lujia Wang; Chenchen Feng; Guanxiong Ding; Qiang Ding; Zhongwen Zhou; Haowen Jiang; Zhong Wu
Journal:  Tumour Biol       Date:  2013-11-17

Review 4.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

5.  An analysis of the polymorphisms of the GLUT1 gene in urothelial cell carcinomas of the bladder and its correlation with p53, Ki67 and GLUT1 expressions.

Authors:  C Xu; X Yang; Y Wang; N Ding; R Han; Y Sun; Y Wang
Journal:  Cancer Gene Ther       Date:  2017-05-19       Impact factor: 5.987

6.  P27(Kip1) and Ki-67 expression analysis in transitional cell carcinoma of the bladder.

Authors:  Bartosz Dybowski; Jolanta Kupryjańczyk; Alina Rembiszewska; Roman Pykało; Andrzej Borkowski
Journal:  Urol Res       Date:  2003-09-27

7.  Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression.

Authors:  Adam S Feldman; Jacqueline Banyard; Chin-Lee Wu; W Scott McDougal; Bruce R Zetter
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 8.  Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

Authors:  Anirban P Mitra; Donna E Hansel; Richard J Cote
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

9.  Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.

Authors:  Wassim Kassouf; Peter C Black; Tomasz Tuziak; Jolanta Bondaruk; Sangkyou Lee; Gordon A Brown; Liana Adam; Caimiao Wei; Keith Baggerly; Menashe Bar-Eli; David McConkey; Bogdan Czerniak; Colin P Dinney
Journal:  J Urol       Date:  2007-11-19       Impact factor: 7.450

Review 10.  Molecular targets and targeted therapies in bladder cancer management.

Authors:  Ramy F Youssef; Anirban P Mitra; Georg Bartsch; Peter A Jones; Donald G Skinner; Richard J Cote
Journal:  World J Urol       Date:  2008-11-28       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.